Data as of Apr 17
| +0.26 / +0.78%|
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. It is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus. These inhibitors include members of the direct acting antiviral inhibitor classes - protease, NS5A and nucleotide polymerase - as well as a host-targeted antiviral inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community methicillin-resistant Staphylococcus aureus infections. Enanta Pharmaceuticals was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
|Jay R. Luly||President, Chief Executive Officer & Director|
|Paul J. Mellett||Chief Financial Officer & Senior VP-Administration|
|Yat-Sun Or||CSO, Senior VP-Research & Development|
|Timothy D. Ocain||Senior VP-New Product Strategy & Development|
|Carol Miceli||Director-Investor Relations|